(MTVA)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd.
| Name | Position |
|---|---|
| Dr. Mi-Kyung Kim | Chief Scientific Officer |
| Dr. W. Christopher Fang M.D. | Consulting Chief Medical Officer & Advisor |
| Mr. Heon Kim Hyung | CEO, President & Director |
| Mr. Marshall H. Woodworth | Chief Financial Officer |
| Mr. Michael C. Pine | Senior Vice President of Business Development Advisor |
| Mr. Robert Homolka | Senior Vice President of Clinical Operations |
| Date | Type | Document |
|---|---|---|
| 2026-03-18 | 8-K | mtva-20260318x8k.htm |
| 2026-01-27 | 8-K | mtva-20260123x8k.htm |
| 2026-01-15 | S-1MEF | tm2528002d20_s1mef.htm |
| 2026-01-12 | S-1/A | tm2528002-13_s1a.htm |
| 2026-01-05 | 8-K | tm2528002d9_8k.htm |
| 2025-12-19 | 8-K | tm2533992d1_8k.htm |
| 2025-12-02 | 8-K | mtva-20251202x8k.htm |
| 2025-11-26 | 8-K | mtva-20251126x8k.htm |
| 2025-11-07 | 8-K | mtva-20251107x8k.htm |
| 2025-11-06 | 10-Q | mtva-20250930x10q.htm |